Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  American Journal of Human Genetics

• Publication date

  2000-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1086/303059PMID 10903931PMCID PMC1287532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors.

  2000cited by this paper
• BMP type II receptor is required for gastrulation and early development of mouse embryos.

  2000influential reference
• Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.

  2000influential reference
• The molecular basis of lung morphogenesis.

  2000cited by this paper
• BMP2-induced Apoptosis Is Mediated by Activation of the TAK1-p38 Kinase Pathway That Is Negatively Regulated by Smad6*

  2000influential reference
• Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms.

  2000influential reference
• A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION

  2000cited by this paper
• A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission.

  1999influential reference
• Antiproliferatiye effects of recombinant human bone morphogenetic protein‐2 on human tumor colony‐forming units

  1998cited by this paper
• TGF-beta signal transduction.

  1998cited by this paper
• Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection.

  1998cited by this paper
• Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

  1998cited by this paper
• Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.

  1997influential reference
• Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium.

  1997cited by this paper
• cDNA cloning and genomic organization of the mouse BMP type II receptor.

  1997cited by this paper
• Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography.

  1997cited by this paper
• Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• Parametric and nonparametric linkage analysis: a unified multipoint approach.

  1996influential reference
• Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2

  1996cited by this paper
• Meeting Highlights American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996

  1996cited by this paper
• Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

  1996cited by this paper
• Mutually Exclusive Interactions between Factors Binding to Adjacent Sp1 and AT-rich Elements Regulate Gastrin Gene Transcription in Insulinoma Cells (*)

  1995cited by this paper
• Identification of a Human Type II Receptor for Bone Morphogenetic Protein-4 That Forms Differential Heteromeric Complexes with Bone Morphogenetic Protein Type I Receptors (*)

  1995influential reference
• Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs

  1995influential reference
• Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension.

  1995cited by this paper
• Inactive type II and type I receptors for TGF beta are dominant inhibitors of TGF beta-dependent transcription.

  1995cited by this paper
• Inactive Type II and Type I Receptors for TGFβ Are Dominant Inhibitors of TGFβ-dependent Transcription (*)

  1995cited by this paper
• Cloning and characterization of a human type II receptor for bone morphogenetic proteins.

  1995influential reference
• Cloning of a Novel Type II Serine/Threonine Kinase Receptor through Interaction with the Type I Transforming Growth Factor-β Receptor (*)

  1995influential reference
• Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients.

  1995cited by this paper
• Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1

  1994cited by this paper
• Immunologic Disturbances in Primary Pulmonary Hypertension

  1994cited by this paper
• Faster sequential genetic linkage computations.

  1993influential reference
• Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region

  1993influential reference
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper
• Basic local alignment search tool.

  1990influential reference
• The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

  1988cited by this paper
• PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY

  1987cited by this paper
• Pulmonary hypertension and fenfluramine

  1982cited by this paper
• Pulmonary hypertension and fenfluramine

  1981cited by this paper

• BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity

  2025cites this paper
• Signaling pathways and targeted therapy for pulmonary hypertension

  2025cites this paper
• Pathobiologie und Genetik

  2025cites this paper
• Issues in diagnosis of pulmonary hypertension

  2025cites this paper
• Nitazoxanide reverses pulmonary vascular remodeling in pulmonary hypertension by targeting the IMPA1-RAGE signaling axis.

  2025cites this paper
• Multiomics Integration for Identifying Treatment Targets, Drug Development, and Diagnostic Designs in PAH

  2025cites this paper
• Targeted delivery of BMPR2 mRNA attenuates pulmonary arterial hypertension by reversing pulmonary vascular remodeling

  2025cites this paper
• Rare variants in PAH-related genes associate with a distinct vasculopathy phenotype and worse outcomes in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension.

  2025cites this paper
• Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series)

  2025cites this paper
• Introducing Historical Vignettes in Pulmonary Circulation.

  2025cites this paper
• High-altitude pulmonary hypertension: a comprehensive review of mechanisms and management

  2025cites this paper
• Integrating pharmacogenetics, multi‐omics and machine learning in the novel therapeutic view of pulmonary hypertension

  2025cites this paper
• Pathogenic Concepts in Pulmonary Arterial Hypertension Revisited - A Multigenerational Perspective.

  2025cites this paper
• Adaptation of ACMG/AMP Guidelines for Clinical Classification of BMPR2 Variants in Pulmonary Arterial Hypertension Resolves Variants of Unclear Pathogenicity in ClinVar

  2025cites this paper
• State of the Art in Pulmonary Arterial Hypertension: Molecular Basis, Imaging Modalities, and Right Heart Failure Treatment

  2025cites this paper
• In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension

  2025cites this paper
• Liver Bypass in the Development of Pathogen-associated Pulmonary Vascular Disease: Contribution of Mesocaval and Portosystemic Shunts.

  2025cites this paper
• Mas1 Receptor Activation is Necessary and Sufficient to Transduce ACE2 Effect in PAH, But Ang(1‐7) Alone is Insufficient

  2025cites this paper
• Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).

  2025cites this paper
• Therapeutic potential of allosteric HECT E3 ligase inhibition

  2025cites this paper
• SOX17 variants are associated with severe pulmonary arterial hypertension with and without congenital heart disease.

  2025cites this paper
• Frontiers in Pulmonary Hypertension: A Comprehensive Insight of Etiological Advances.

  2024cites this paper
• Genetics and precision genomics approaches to pulmonary hypertension

  2024cites this paper
• Advances in the potential of nebulized inhalation for the treatment of pulmonary arterial hypertension.

  2024cites this paper
• Unraveling the Genetic Landscape of Pulmonary Arterial Hypertension in Indian Patients: A Transcriptome Study.

  2024cites this paper
• Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation.

  2024cites this paper
• Increased BMP-Responsive Transcription Factors in Distinct Endothelial and Mesenchymal Cells in PAH.

  2024cites this paper
• The Monocrotaline Rat Model of Right Heart Disease Induced by Pulmonary Artery Hypertension

  2024cites this paper
• Digital Spatial Profiling Identifies Distinct Molecular Signatures of Vascular Lesions in Pulmonary Arterial Hypertension.

  2024cites this paper
• Functional validation of EIF2AK4 (GCN2) missense variants associated with pulmonary arterial hypertension

  2024cites this paper
• Genetic background of pulmonary (vascular) diseases – how much is written in the codes?

  2024cites this paper
• SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cells.

  2024cites this paper
• Adaptation of ACMG/AMP guidelines for clinical classification of BMPR2 variants in Pulmonary Arterial Hypertension resolves variants of unclear pathogenicity in ClinVar.

  2024cites this paper
• Rôle des canaux ioniques dans la physiopathologie de l’hypertension artérielle pulmonaire

  2024cites this paper
• Systemic juvenile idiopathic arthritis–associated lung disease: A retrospective cohort study

  2024cites this paper
• Efficacy and Safety of Sotatercept in Pulmonary Arterial Hypertension: A Systematic Review

  2024cites this paper
• Parental smoking and pulmonary arterial hypertension in infants: A cohort study

  2024cites this paper
• [Genetic counselling and testing in pulmonary arterial hypertension - A consensus statement on behalf of the International Consortium for Genetic Studies in PAH - French version].

  2023cites this paper
• Sex- and Gender-Related Aspects in Pulmonary Hypertension.

  2023cites this paper
• Noncoding RNAs in Pulmonary Arterial Hypertension: Current Knowledge and Translational Perspectives.

  2023cites this paper
• Clinical features of pulmonary arterial hypertension associated with systemic sclerosis

  2023cites this paper
• Germline and Somatic Mutations in DNA Methyltransferase 3A (DNMT3A) Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: Implications for Associated PAH

  2023cites this paper
• Possible Hereditary Pulmonary Arterial Hypertension: from Clinical to Genetic Investigation in Precision Medicine Era

  2023cites this paper
• Differential drug response in pulmonary arterial hypertension: The potential for precision medicine

  2023cites this paper
• Emergence of disease specific endothelial and stromal cell populations involved in arterial remodeling during development of pulmonary arterial hypertension

  2023cites this paper
• Pulmonary arterial hypertension drugs can partially restore altered angiogenic capacities in bmpr2‐silenced human lung microvascular endothelial cells

  2023cites this paper
• Pulmonary arterial hypertension.

  2023cites this paper
• Case report: Progressive pulmonary artery hypertension in a case of megalencephaly-capillary malformation syndrome

  2023cites this paper
• Pathophysiology and new advances in pulmonary hypertension

  2023cites this paper
• ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport

  2023cites this paper
• The Future of PAH Treatment

  2023cites this paper
• Genetische Diagnostik und molekulare Ansätze bei pulmonalarterieller Hypertonie

  2023cites this paper
• Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension

  2023cites this paper
• The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges

  2023cites this paper
• Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension

  2023influential citation
• Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension.

  2023cites this paper
• Vascular-Parenchymal Crosstalk Promotes Lung Fibrosis Through BMPR2 Signaling.

  2023cites this paper
• Review of the British Thoracic Society Winter Meeting 23 November 2022 23–25 November 2022

  2023cites this paper
• Advances in the discovery of drugs that treat pulmonary arterial hypertension

  2023cites this paper
• Emergence of disease-specific endothelial and stromal cell populations responsible for arterial remodeling during development of pulmonary arterial hypertension

  2023cites this paper
• Metabolic reprogramming, oxidative stress, and pulmonary hypertension

  2023cites this paper
• The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling

  2022cites this paper
• Hypoxia‐induced pulmonary hypertension upregulates eNOS and TGF‐β contributing to sex‐linked differences in BMPR2 +/R899X mutant mice

  2022cites this paper
• Novel hub genes associated with pulmonary artery remodeling in pulmonary hypertension

  2022cites this paper
• Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

  2022cites this paper
• Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels and Ca2+ Signaling.

  2022cites this paper
• Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study

  2022cites this paper
• Defining the Clinical Validity of Genes Reported to Cause Pulmonary Arterial Hypertension

  2022cites this paper
• Molecular Pathways in Pulmonary Arterial Hypertension

  2022cites this paper
• Endothelin-1 Alters BMP Signaling to Promote Proliferation of Pulmonary Artery Smooth Muscle Cells.

  2022cites this paper
• The Impact of Socioeconomic, Racial, and Ethnic Disparities on Pulmonary Hypertension Diagnosis and Treatment

  2022cites this paper
• New progress in diagnosis and treatment of pulmonary arterial hypertension

  2022cites this paper
• Endothelial mechanosensing: a forgotten target to treat vascular remodeling in hypertension?

  2022cites this paper
• MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension

  2022cites this paper
• Evolving Concepts in Endothelial Pathobiology of Pulmonary Arterial Hypertension.

  2022cites this paper
• Description of Two New Cases of AQP1 Related Pulmonary Arterial Hypertension and Review of the Literature

  2022cites this paper
• New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis

  2022cites this paper
• Targeting BMPR-II in pulmonary arterial hypertension: a case of Hercules versus the Hydra?

  2022cites this paper
• Computed tomography evaluation of pediatric pulmonary hypertension

  2022cites this paper
• The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure

  2022cites this paper
• An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertension

  2022influential citation
• Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling

  2022cites this paper
• Stem cell therapy for pulmonary arterial hypertension: An update.

  2022cites this paper
• Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

  2022cites this paper
• Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension

  2022cites this paper
• Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH

  2022cites this paper
• Pursuing Functional Biomarkers in Complex Disease: Focus on Pulmonary Arterial Hypertension.

  2022cites this paper
• Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice

  2022cites this paper
• Cold exposure aggravates pulmonary arterial hypertension through increased miR-146a-5p, miR-155-5p and cytokines TNF-α, IL-1β, and IL-6.

  2021cites this paper
• BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series

  2021cites this paper
• Fibroblast growth factors: the keepers of endothelial normalcy.

  2021cites this paper
• Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension

  2021cites this paper
• Novel Pharmacological Targets for Pulmonary Arterial Hypertension.

  2021cites this paper
• Pulmonary Arterial Hypertension

  2021cites this paper
• Case Report: BMPR2-Targeted MinION Sequencing as a Tool for Genetic Analysis in Patients With Pulmonary Arterial Hypertension

  2021cites this paper
• Exercise-induced pulmonary hypertension in HIV patients: Association with poorer clinical and immunological status.

  2021cites this paper
• Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

  2021cites this paper
• Screening asymptomatic BMPR2 mutation carriers: a new frontier for pulmonary hypertension physicians?

  2021cites this paper
• Roles of Genetic Predisposition in the Sex Bias of Pulmonary Pathophysiology, as a Function of Estrogens : Sex Matters in the Prevalence of Lung Diseases.

  2021cites this paper
• Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension

  2021cites this paper